Literature DB >> 17240786

Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.

D Jinga1, Maria Stefanescu, A Blidaru, Ileana Condrea, Gina Pistol, Cristiana Matache.   

Abstract

In this study, the levels of matrix metalloproteinases MMP-2 and MMP-9 were simultaneously analyzed with the levels of their tissue natural inhibitors TIMP-1 and TIMP-2 in sera of patients with breast tumors. At the same time, the activity of these two matrix metalloproteinases was evaluated. The decrease of TIMP-2 level in sera from patients with breast cancer as well as an imbalance between MMP-2 and TIMP-2 in neoplasic processes were found. The serum levels of MMP-2, MMP-9 and TIMP-1 were comparable between the patients with breast cancer and benign tumors. These experimental studied parameters were found to correlate with some of clinicopathological disease variables (TNM or pTNM staging system, tumor size and node invasion) suggesting their potential value for diagnosis and prognosis of breast cancer. Matrix metalloproteinases or their natural inhibitors and tumor markers (CA15.3 and CEA) not correlated between but, each of them correlated with another clinicopathological disease variable, suggesting their usefulness in the evaluation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 17240786

Source DB:  PubMed          Journal:  Roum Arch Microbiol Immunol        ISSN: 1222-3891


  2 in total

Review 1.  Breast cancer progression: insights into multifaceted matrix metalloproteinases.

Authors:  Vincent Chabottaux; Agnès Noel
Journal:  Clin Exp Metastasis       Date:  2007-10-30       Impact factor: 5.150

2.  In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer.

Authors:  Emilia S Olson; Todd A Aguilera; Tao Jiang; Lesley G Ellies; Quyen T Nguyen; Edmund H Wong; Larry A Gross; Roger Y Tsien
Journal:  Integr Biol (Camb)       Date:  2009-05-11       Impact factor: 2.192

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.